ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Testosterone after Prostate Cancer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 257169" data-attributes="member: 13851"><p><em>Testosterone treatment for hypogonadal men with organ-confined prostate cancer and unequivocal hypogonadism is under scrutiny for its potential association with cancer recurrence. Physicians are cautious due to the testosterone dependence of metastatic prostate cancer. Previous studies lacked clear evidence of unequivocal hypogonadism in men receiving testosterone treatment for treated prostate cancer. The goal of this study was to examine the relationship between testosterone treatment and cancer recurrence in men with unequivocal hypogonadism and organ-confined prostate cancer.</em></p><p></p><p></p><p></p><p></p><p><strong>Take-home points:</strong></p><ul> <li data-xf-list-type="ul"><em><em>All patients in the study were confirmed to be hypogonadal based on morning testosterone values, with a criterion of <220 ng/dL.</em></em></li> <li data-xf-list-type="ul"><em><em>The majority of men (14 out of 16) had hypogonadism due to recognizable pituitary or testicular causes, meeting the FDA criterion for testosterone replacement.</em></em></li> <li data-xf-list-type="ul"><em><em>The study provided clear documentation of cancer grade, surgical extent, and regular monitoring for a median duration of 5 years.</em></em></li> <li data-xf-list-type="ul"><em><em>The results specifically apply to men who underwent radical prostatectomy and had organ-confined prostate cancer.</em></em></li> <li data-xf-list-type="ul"><em><em>The results do not apply to men with evidence of cancer spread outside the prostate or those treated with radiation.</em></em></li> <li data-xf-list-type="ul"><em><em>The study's limitations include its retrospective nature, a relatively small number of participants, and some individuals being observed for less than 3 years.</em></em></li> <li data-xf-list-type="ul"><em><em>Testosterone treatment of these men did not show biochemical evidence of cancer recurrence.</em></em></li> <li data-xf-list-type="ul"><em><em>Further confirmation from larger studies would support the safety of this treatment for men meeting the specified criteria.</em></em></li> </ul></blockquote><p></p>
[QUOTE="madman, post: 257169, member: 13851"] [I]Testosterone treatment for hypogonadal men with organ-confined prostate cancer and unequivocal hypogonadism is under scrutiny for its potential association with cancer recurrence. Physicians are cautious due to the testosterone dependence of metastatic prostate cancer. Previous studies lacked clear evidence of unequivocal hypogonadism in men receiving testosterone treatment for treated prostate cancer. The goal of this study was to examine the relationship between testosterone treatment and cancer recurrence in men with unequivocal hypogonadism and organ-confined prostate cancer.[/I] [B]Take-home points:[/B] [LIST] [*][I][I]All patients in the study were confirmed to be hypogonadal based on morning testosterone values, with a criterion of <220 ng/dL.[/I][/I] [*][I][I]The majority of men (14 out of 16) had hypogonadism due to recognizable pituitary or testicular causes, meeting the FDA criterion for testosterone replacement.[/I][/I] [*][I][I]The study provided clear documentation of cancer grade, surgical extent, and regular monitoring for a median duration of 5 years.[/I][/I] [*][I][I]The results specifically apply to men who underwent radical prostatectomy and had organ-confined prostate cancer.[/I][/I] [*][I][I]The results do not apply to men with evidence of cancer spread outside the prostate or those treated with radiation.[/I][/I] [*][I][I]The study's limitations include its retrospective nature, a relatively small number of participants, and some individuals being observed for less than 3 years.[/I][/I] [*][I][I]Testosterone treatment of these men did not show biochemical evidence of cancer recurrence.[/I][/I] [*][I][I]Further confirmation from larger studies would support the safety of this treatment for men meeting the specified criteria.[/I][/I] [/LIST] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Testosterone after Prostate Cancer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top